Best Dihydrofolate Reductase Inhibitor Antimalarial for aids-related opportunistic infections
2 Dihydrofolate Reductase Inhibitor Antimalarial drugs indicated for aids-related opportunistic infections, ranked by our independent rating. The current highest-rated is pyrimethamine. Compare them with all treatments for aids-related opportunistic infections or the full Dihydrofolate Reductase Inhibitor Antimalarial class. Not medical advice — always consult a professional.
Top dihydrofolate reductase inhibitor antimalarial for aids-related opportunistic infections: 1. Pyrimethamine · 2. Daraprim
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Pyrimethamine | 64/100 | Prescription | $4110 | View → |
| 2 | Daraprim | Not yet rated | Prescription | $4110 | View → |
Full ranking · 2 drugs
Frequently asked
- What is the best dihydrofolate reductase inhibitor antimalarial for aids-related opportunistic infections?
- By our independent rating, pyrimethamine currently ranks highest among Dihydrofolate Reductase Inhibitor Antimalarial drugs used for aids-related opportunistic infections. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which dihydrofolate reductase inhibitor antimalarial drugs treat aids-related opportunistic infections?
- pharmaranks lists 2 Dihydrofolate Reductase Inhibitor Antimalarial products indicated for aids-related opportunistic infections, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.